US4061791A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Anti-allergic oxanilate compounds
Assignee: Pharmacia and Upjohn Co
•
Filing: 1975-12-29
•
Granted: 1977-12-06
•
Expires: 1995-12-29
Abstract
Abstract A method of treating mammals for allergy and anaphylactic reactions of a reagin or non-reagin mediated nature which comprises administering prophylactically to said mammal an anti-allergy or anaphylactic reaction effective amount of a compound of the formula ##STR1## Novel compounds and compositions are also claimed.
Inventors
- 👤 Charles M. Hall
- 👤 John B. Wright
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-11-08 17:58
CPC Classifications
A; A61; A61K; A61K31/00; A61K31/275; A61K31/21; A61K31/215; A61K31/235; A61K31/24; C; C07; C07C; C07C255/00; C07C255/49; C07C255/58
Claims Analysis
Total Claims: 30
Claim 1
Independent Claim
120 words
A pharmaceutical composition which comprises as the sole active ingredient an anti-asthma, allergic rhinitis, urticara, or food allergy effective amount of a compound of the formula ##STR16## wherein R is selected from the group consisting of hydrogen, a physiologically acceptable metal or amine cation, alkyl of one to six carbon atoms, inclusive, and ##STR17## wherein n is 0, 1 or 2; R 1 and R 2 are the same or different and are selected from the group consisting of hydrogen, halogen, nitro, cyano and ##STR18## with the proviso that when one or both of R 1 and R 2 are ##STR19## groups on a phenylene ring are not ortho to each other; and ##STR20## in association with a pharmaceutical carrier.
Claim 2
Dependent Claim
120 words
A pharmaceutical composition which comprises as the sole active ingredient an anti-asthma, allergic rhinitis, urticara, or food allergy effective amount of a compound of the formula ##STR16## wherein R is selected from the group consisting of hydrogen, a physiologically acceptable metal or amine cation, alkyl of one to six carbon atoms, inclusive, and ##STR17## wherein n is 0, 1 or 2; R 1 and R 2 are the same or different and are selected from the group consisting of hydrogen, halogen, nitro, cyano and ##STR18## with the proviso that when one or both of R 1 and R 2 are ##STR19## groups on a phenylene ring are not ortho to each other; and ##STR20## in association with a pharmaceutical carrier.
Claim 3
Dependent Claim
34 words
A pharmaceutical composition in accordance with claim 1 wherein R is selected from the group consisting of hydrogen, a physiologically acceptable metal or amine cation and alkyl of one to six carbon atoms, inclusive.
Claim 4
Dependent Claim
57 words
A pharmaceutical composition in accordance with claim 2 wherein R is selected from the group consisting of hydrogen, a physiologically acceptable metal or amine cation and alkyl of one to three carbon atoms, inclusive; R 1 and R 2 are the same or different and are selected from the group consisting of hydrogen, halogen, cyano and nitro.
Claim 5
Dependent Claim
20 words
A pharmaceutical composition in accordance with claim 2 wherein the pharmaceutical carrier is strongly resistant to degradation from ultraviolet light.
Claim 6
Dependent Claim
20 words
A pharmaceutical composition in accordance with claim 3 wherein the pharmaceutical carrier is strongly resistant to degradation from ultraviolet light.
Claim 7
Dependent Claim
20 words
A pharmaceutical composition in accordance with claim 1 wherein the pharmaceutical carrier is strongly resistant to degradation from ultraviolet light.
Claim 8
Dependent Claim
15 words
A composition in accordance with claim 1 wherein R 1 and R 2 are hydrogen.
Claim 9
Dependent Claim
13 words
A composition in accordance with claim 1 wherein the compound is diethyl 3'-[m-(1-carboxyformamido)benzamido]oxanilate.
Claim 10
Dependent Claim
14 words
A composition in accordance with claim 1 wherein the compound is 4'-[m-(1-carboxyformamido)benzamido]-3'-cyano oxanilic acid.
Claim 11
Dependent Claim
14 words
A composition in accordance with claim 1 wherein the compound is diethyl 4'-[m-(1-carboxyformamido)benzamido]-3'-cyano oxanilate.
Claim 12
Dependent Claim
118 words
A pharmaceutical composition which comprises an anti-asthma, allergic rhinitis, urticaria or food allergy effective amount of a compound of the formula ##STR21## wherein R is selected from the group consisting of hydrogen, a physiologically acceptable metal or amine cation, alkyl of one to six carbon atoms, inclusive, and ##STR22## wherein n is 0, 1 or 2; R 1 and R 2 are the same or different and are selected from the group consisting of hydrogen, halogen, nitro, cyano and ##STR23## with the proviso that when one or both of R 1 and R 2 are ##STR24## groups on a phenylene ring are not ortho to each other; and ##STR25## in association with a pharmaceutical carrier suitable for inhalation.
Claim 13
Dependent Claim
118 words
A pharmaceutical composition which comprises an anti-asthma, allergic rhinitis, urticaria or food allergy effective amount of a compound of the formula ##STR21## wherein R is selected from the group consisting of hydrogen, a physiologically acceptable metal or amine cation, alkyl of one to six carbon atoms, inclusive, and ##STR22## wherein n is 0, 1 or 2; R 1 and R 2 are the same or different and are selected from the group consisting of hydrogen, halogen, nitro, cyano and ##STR23## with the proviso that when one or both of R 1 and R 2 are ##STR24## groups on a phenylene ring are not ortho to each other; and ##STR25## in association with a pharmaceutical carrier suitable for inhalation.
Claim 14
Dependent Claim
26 words
A pharmaceutical composition in accordance with claim 11 wherein R is selected from the group consisting of hydrogen and a physiologically acceptable metal or amine cation.
Claim 15
Dependent Claim
15 words
A composition in accordance with claim 11 wherein R 1 and R 2 are hydrogen.
Claim 16
Dependent Claim
100 words
A pharmaceutical composition which comprises an anti-asthma, allergic rhinitis, urticaria, or food allergy effective amount of a compound of the formula ##STR26## wherein R is selected from the group consisting of hydrogen and a physiologically acceptable metal or amine cation; R 1 and R 2 are the same or different and are selected from the group consisting of hydrogen, halogen, nitro, cyano and ##STR27## with the proviso that when one or both of R 1 and R 2 are ##STR28## , groups on a phenylene ring are not ortho to each other; and ##STR29## in association with a pharmaceutical carrier.
Claim 17
Dependent Claim
100 words
A pharmaceutical composition which comprises an anti-asthma, allergic rhinitis, urticaria, or food allergy effective amount of a compound of the formula ##STR26## wherein R is selected from the group consisting of hydrogen and a physiologically acceptable metal or amine cation; R 1 and R 2 are the same or different and are selected from the group consisting of hydrogen, halogen, nitro, cyano and ##STR27## with the proviso that when one or both of R 1 and R 2 are ##STR28## , groups on a phenylene ring are not ortho to each other; and ##STR29## in association with a pharmaceutical carrier.
Claim 18
Dependent Claim
32 words
A pharmaceutical composition in accordance with claim 14 wherein R 1 and R 2 are the same or different and are selected from the group consisting of hydrogen, halogen, cyano and nitro.
Claim 19
Dependent Claim
13 words
A composition in accordance with claim 14 wherein the compound is 3'-[m-(1-carboxyformamido)benzamido]-oxanilic acid.
Claim 20
Independent Claim
131 words
A method for treating a mammal for asthma, allergic rhinitis, urticaria or food allergy which comprises prophylactically adminstering to said mammal an anti-asthma, allergic rhinitis, urticara or food allergy effective amount of a compound of the formula ##STR30## wherein R is selected from the group consisting of hydrogen, a physiologically acceptable metal or amine cation, alkyl of one to six carbon atoms, inclusive, and ##STR31## wherein n is 0, 1 or 2; R 1 and R 2 are the same or different and are selected from the group consisting of hydrogen, halogen, nitro, cyano and ##STR32## with the proviso that when one or both of R 1 and R 2 are ##STR33## groups on a phenylene ring are not ortho to each other; and ##STR34## in association with a pharmaceutical carrier.
Claim 21
Independent Claim
131 words
A method for treating a mammal for asthma, allergic rhinitis, urticaria or food allergy which comprises prophylactically adminstering to said mammal an anti-asthma, allergic rhinitis, urticara or food allergy effective amount of a compound of the formula ##STR30## wherein R is selected from the group consisting of hydrogen, a physiologically acceptable metal or amine cation, alkyl of one to six carbon atoms, inclusive, and ##STR31## wherein n is 0, 1 or 2; R 1 and R 2 are the same or different and are selected from the group consisting of hydrogen, halogen, nitro, cyano and ##STR32## with the proviso that when one or both of R 1 and R 2 are ##STR33## groups on a phenylene ring are not ortho to each other; and ##STR34## in association with a pharmaceutical carrier.
Claim 22
Dependent Claim
33 words
A method in accordance with claim 17 wherein R is selected from the group consisting of hydrogen, a physiologically acceptable metal or amine cation and alkyl of one to six carbon atoms, inclusive.
Claim 23
Dependent Claim
56 words
A method in accordance with claim 18 wherein R is selected from the group consisting of hydrogen, a physiologically acceptable metal or amine cation and alkyl of one to three carbon atoms, inclusive; R 1 and R 2 are the same or different and are selected from the group consisting of hydrogen, halogen, cyano and nitro.
Claim 24
Dependent Claim
15 words
A method in accordance with claim 17 wherein R 1 and R 2 are hydrogen.
Claim 25
Dependent Claim
13 words
A method in accordance with claim 17 wherein the compound is 3'-[m-(1-carboxyformamido)benzamido]-oxanilic acid.
Claim 26
Dependent Claim
13 words
A method in accordance with claim 17 wherein the compound is diethyl 3'-[m-(1-carboxyformamido)benzamido]oxanilate.
Claim 27
Dependent Claim
13 words
A method in accordance with claim 17 wherein the compound is di-tris(hydroxymethyl)methylammonium 3'-[m-(1-carboxyformamido)benzamido]-oxanilate.
Claim 28
Dependent Claim
13 words
A method in accordance with claim 17 wherein the compound is di-tris(hydroxymethyl)methylammonium 3'[m-(1-carboxyformamido]benzamido]-oxanilate.
Claim 29
Dependent Claim
14 words
A method in accordance with claim 17 wherein the compound is 4'-[m-(1-carboxyformamido)benzamido]-3'-cyano oxanilic acid.
Claim 30
Dependent Claim
14 words
A method in accordance with claim 17 wherein the compound is diethyl 4'-[m-(1-carboxyformamido)benzamido]-3'-cyano oxanilate.
References Cited (Backward Citations)
US3852324A
Cited
US3966965A
Cited
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1980-12-05 | 1981-06-06 | 1981-12-06 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 1984-12-05 | 1985-06-06 | 1985-12-06 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 1988-12-05 | 1989-06-06 | 1989-12-06 | $7700.00 | Window Closed / Lapsed |